Early research from Penn Medicine suggests that new mRNA vaccines could prevent food and seasonal allergies by stopping allergens from triggering immune reactions and inflammation, showing promise for future allergy treatments.
Researchers have discovered that the rare blood clotting disorder associated with early COVID-19 vaccines, such as AstraZeneca and Johnson & Johnson, may be caused by two out-of-control immune reactions happening simultaneously. One of these reactions was already known, but the second was recently identified. Understanding the mechanisms behind this clotting disorder could lead to better treatments and potentially make vaccines safer for individuals prone to this side effect. By modifying the adenovirus vector used in these vaccines, researchers may be able to eliminate the factor triggering the clotting response. Further research is needed to fully unravel the complex pathways involved in this disorder and prevent its occurrence.